Danske Bank A S Makes New $80.38 Million Investment in Stryker Corporation $SYK

Danske Bank A S purchased a new stake in shares of Stryker Corporation (NYSE:SYK) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 217,426 shares of the medical technology company’s stock, valued at approximately $80,376,000. Danske Bank A S owned about 0.06% of Stryker at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in SYK. Davis R M Inc. raised its position in Stryker by 1.8% in the 3rd quarter. Davis R M Inc. now owns 138,732 shares of the medical technology company’s stock worth $51,285,000 after purchasing an additional 2,512 shares during the period. Terra Alpha Investments LLC purchased a new stake in Stryker during the third quarter valued at about $1,216,000. Kepler Cheuvreux Suisse SA bought a new position in shares of Stryker during the third quarter valued at about $27,952,000. Diversified Trust Co grew its stake in shares of Stryker by 45.6% during the third quarter. Diversified Trust Co now owns 12,445 shares of the medical technology company’s stock valued at $4,601,000 after buying an additional 3,899 shares during the last quarter. Finally, SVB Wealth LLC purchased a new position in shares of Stryker in the second quarter worth about $4,785,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of the business’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the transaction, the director directly owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. The trade was a 9.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 5.20% of the company’s stock.

Stryker Trading Down 0.1%

SYK opened at $349.19 on Wednesday. Stryker Corporation has a one year low of $328.23 and a one year high of $404.87. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.89 and a quick ratio of 1.21. The business has a 50 day simple moving average of $364.88 and a two-hundred day simple moving average of $366.76. The firm has a market capitalization of $133.63 billion, a price-to-earnings ratio of 41.57, a PEG ratio of 2.04 and a beta of 0.85.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, topping analysts’ consensus estimates of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The firm had revenue of $7.17 billion for the quarter, compared to analyst estimates of $7.12 billion. During the same period last year, the company earned $4.01 EPS. The business’s quarterly revenue was up 11.4% compared to the same quarter last year. Analysts predict that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be issued a $0.88 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker’s payout ratio is 41.90%.

Wall Street Analysts Forecast Growth

SYK has been the subject of several analyst reports. Weiss Ratings restated a “hold (c+)” rating on shares of Stryker in a report on Monday, December 22nd. Evercore set a $390.00 price objective on Stryker in a research report on Monday, January 5th. TD Cowen lowered Stryker from a “buy” rating to a “hold” rating and set a $387.00 price objective for the company. in a research note on Monday, January 26th. Sanford C. Bernstein raised their target price on shares of Stryker from $450.00 to $465.00 and gave the stock an “outperform” rating in a report on Friday, January 9th. Finally, Truist Financial decreased their target price on shares of Stryker from $400.00 to $392.00 and set a “hold” rating on the stock in a research note on Thursday, December 18th. Fourteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and an average target price of $427.50.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.